Method for treating dysmenorrhea with a uterine therapeutic system

Claim 1

A method for treating dysmenorrhea in a warm blooded animal which method comprises administering to the uterus of the animal from a means sized, shaped and adapted for placement in the uterus a therapeutically effective amount of a progestational steroid for a prolonged period of time to impart relief from said dysmenorrhea.

Claim 2

A method for treating dysmenorrhea in a warm blooded animal which method comprises administering to the uterus of the animal from a means sized, shaped and adapted for placement in the uterus a therapeutically effective amount of a progestational steroid for a prolonged period of time to impart relief from said dysmenorrhea.

Claim 9

A method for the management of dysmenorrhea which comprises administering to the uterus of a warm blooded animal having dysmenorrhea a therapeutically effective amount of a progestational hormone having the following formula: ##STR5## wherein R 1 , R 2 and R 3 are independently selected from the group consisting of hydrogen and lower alkyl; R 4 is a member selected from the group consisting of hydroxyl and acyl; R 5 and R 6 are independently selected from the group consisting of hydrogen, hydroxyl and acyloxy; R 5 and R 6 taken together consists of a ##STR6## group wherein w is a lower alkyl and p is a member selected from the group consisting of lower alkyl and phenyl and x is a member selected from the group consisting of H 2 and oxygen.

Claim 10

A method for the management of dysmenorrhea which comprises administering to the uterus of a warm blooded animal having dysmenorrhea a therapeutically effective amount of a progestational hormone having the following formula: ##STR5## wherein R 1 , R 2 and R 3 are independently selected from the group consisting of hydrogen and lower alkyl; R 4 is a member selected from the group consisting of hydroxyl and acyl; R 5 and R 6 are independently selected from the group consisting of hydrogen, hydroxyl and acyloxy; R 5 and R 6 taken together consists of a ##STR6## group wherein w is a lower alkyl and p is a member selected from the group consisting of lower alkyl and phenyl and x is a member selected from the group consisting of H 2 and oxygen.

Claim 11

A method for the management of dysmenorrhea which comprises administering to the uterus of a warm blooded animal having dysmenorrhea an effective amount of a progestational hormone having the following formula: ##STR7## wherein x is a member selected from the group consisting of oxygen and H 2 ; R 1 is a member selected from the group consisting of lower alkyl and halogen; R 2 is a member selected from the group consisting of lower alkyl and acyloxy; and R 3 is an acyl moiety.

Claim 12

A method for the management of dysmenorrhea which comprises administering to the uterus of a warm blooded animal having dysmenorrhea an effective amount of a progestational hormone having the following formula: ##STR7## wherein x is a member selected from the group consisting of oxygen and H 2 ; R 1 is a member selected from the group consisting of lower alkyl and halogen; R 2 is a member selected from the group consisting of lower alkyl and acyloxy; and R 3 is an acyl moiety.

Claim 13

A method for the management of dysmenorrhea which comprises administering to the uterus of a warm blooded animal having dysmenorrhea a progestational hormone having the following formula: ##STR8## wherein R 1 is a member selected from the group consisting of hydroxyl and acyloxy; R 2 is a member selected from the group consisting of hydrogen and acyloxy; and R 3 is alkynyl.

Claim 14

A method for the management of dysmenorrhea which comprises administering to the uterus of a warm blooded animal having dysmenorrhea a progestational hormone having the following formula: ##STR8## wherein R 1 is a member selected from the group consisting of hydroxyl and acyloxy; R 2 is a member selected from the group consisting of hydrogen and acyloxy; and R 3 is alkynyl.

Claim 15

A method for the management of dysmenorrhea which comprises administering to the uterus of a warm blooded animal having dysmenorrhea a progestational hormone having the following formula: ##STR9## wherein R 1 is a member selected from the group consisting of hydrogen and lower alkyl; R 2 is a member selected from the group consisting of acyl and acyloxy; and R 3 is a member selected from the group consisting of hydroxyl and lower alkynyl.

Claim 16

A method for the management of dysmenorrhea which comprises administering to the uterus of a warm blooded animal having dysmenorrhea a progestational hormone having the following formula: ##STR9## wherein R 1 is a member selected from the group consisting of hydrogen and lower alkyl; R 2 is a member selected from the group consisting of acyl and acyloxy; and R 3 is a member selected from the group consisting of hydroxyl and lower alkynyl.

Claim 17

A method for treating dysmenorrhea which comprises administering to the uterus of a woman having dysmenorrhea a therapeutically effective amount of a progestational steroid from a uterine therapeutic system in the form of an intrauterine device that releases the steroid selected from the group consisting of Δ 4 -pregnene-3,20-dione; 6α-methyl-4-pregnen-17α-ol-3,2 -dione; 6α-methyl-17α-acetoxyprogesterone; 17α-ethynyl-17β-hydroxy-4-androsten-3-one; 6α-methyl-17-(1-propynyl)testosterone; 17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one; (±)-13-ethyl-17α-ethynyl-17-hydroxygon-4-en-3-one; 17-hydroxy-19-nor-17α-pregn-5(10)-en-20-yn-3-one; 3β ,17β-diacetoxy-17α-ethynyl-4-estrene; 19-nor-17α-pregn-4-en-20-yne-3β,17-diol; 3-(cyclopentoxyl)-19-nor-17α-pregna-3,5-dien-20-yn-17-ol-acetate; 17α-ethynylester-4-en-17β-ol; 17α-acetoxypregn-4-ene-3,20-dione; 17α-hydroxyprogesterone; 17α-hydroxyprogesterone 3-cyclopentyl enol ether; 17α-hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate; 6-chloro-17-hydroxypregna-4,6-diene-3,20-dione acetate; 6,17-dimethylpregna-4,6-diene-3,20-dione; 10α-pregna-4,6-diene3,20-dione; R-16α,17-dihydroxy-pregn-4-ene-3,20-dione; 3-(cyclopentyloxy)pregna-3,5-dien-20-one; 16α,17-dihydroxypregn-4-ene-3,20-dione; 16α,17α-dihydroxy-4-pregnene-3,20-dione, cyclic 16,17-acetal with acetophenone; 17α-ethynyl-5-estren-17β-ol; and 17α-ethynyl-17-hydroxy-estra-4,6,11-trien-3-one, in a controlled and continuous amount over a prolonged period of time.

Claim 18

A method for treating dysmenorrhea which comprises administering to the uterus of a woman having dysmenorrhea a therapeutically effective amount of a progestational steroid from a uterine therapeutic system in the form of an intrauterine device that releases the steroid selected from the group consisting of Δ 4 -pregnene-3,20-dione; 6α-methyl-4-pregnen-17α-ol-3,2 -dione; 6α-methyl-17α-acetoxyprogesterone; 17α-ethynyl-17β-hydroxy-4-androsten-3-one; 6α-methyl-17-(1-propynyl)testosterone; 17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one; (±)-13-ethyl-17α-ethynyl-17-hydroxygon-4-en-3-one; 17-hydroxy-19-nor-17α-pregn-5(10)-en-20-yn-3-one; 3β ,17β-diacetoxy-17α-ethynyl-4-estrene; 19-nor-17α-pregn-4-en-20-yne-3β,17-diol; 3-(cyclopentoxyl)-19-nor-17α-pregna-3,5-dien-20-yn-17-ol-acetate; 17α-ethynylester-4-en-17β-ol; 17α-acetoxypregn-4-ene-3,20-dione; 17α-hydroxyprogesterone; 17α-hydroxyprogesterone 3-cyclopentyl enol ether; 17α-hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate; 6-chloro-17-hydroxypregna-4,6-diene-3,20-dione acetate; 6,17-dimethylpregna-4,6-diene-3,20-dione; 10α-pregna-4,6-diene3,20-dione; R-16α,17-dihydroxy-pregn-4-ene-3,20-dione; 3-(cyclopentyloxy)pregna-3,5-dien-20-one; 16α,17-dihydroxypregn-4-ene-3,20-dione; 16α,17α-dihydroxy-4-pregnene-3,20-dione, cyclic 16,17-acetal with acetophenone; 17α-ethynyl-5-estren-17β-ol; and 17α-ethynyl-17-hydroxy-estra-4,6,11-trien-3-one, in a controlled and continuous amount over a prolonged period of time.

Claim 24

A method for treating dysmenorrhea which method comprises the steps of (a) positioning in the uterus of a woman having dysmenorrhea an intrauterine device sized, shaped and adapted for prolonged retention in the uterus and containing 0.1 milligrams to 5 grams of a progestational steroid and (b) administering from the device from 5 nanograms to 100 micrograms per day of the progestational steroid to the uterus to impart relief from said dysmenorrhea.

Claim 25

A method for treating dysmenorrhea which method comprises the steps of (a) positioning in the uterus of a woman having dysmenorrhea an intrauterine device sized, shaped and adapted for prolonged retention in the uterus and containing 0.1 milligrams to 5 grams of a progestational steroid and (b) administering from the device from 5 nanograms to 100 micrograms per day of the progestational steroid to the uterus to impart relief from said dysmenorrhea.